.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Fouzia Ziad

Hamilton, NZ

Waikato Hospital, Hamilton, NewZealand

Vorsitz

15.09.2023
09:00 – 09:45
Scientific session - Muscle and nerve
Congenital and other hereditary myopathies
Bernhard von Langenbeck (1st floor)
small auditorium, 90 seats
Muscle and Nerve

Vortrag

14.09.2023
ePoster
PS2-NO-A41
Utility of DNA-methylation profiling and Integrated Molecular-Morphologic Meningioma classification as a prognostic biomarker in CNS WHO grade 2 meningiomas – a retrospective feasibility study in a patient cohort with resected meningiomas in New Zealand
14.09.2023
12:45 – 12:51 4 Min. 2 Min.
ePoster Talk
PS2-NO-A41
Utility of DNA-methylation profiling and Integrated Molecular-Morphologic Meningioma classification as a prognostic biomarker in CNS WHO grade 2 meningiomas – a retrospective feasibility study in a patient cohort with resected meningiomas in New Zealand

Weitere Beteiligungen

14.09.2023
ePoster
PS2-NO-A41
Utility of DNA-methylation profiling and Integrated Molecular-Morphologic Meningioma classification as a prognostic biomarker in CNS WHO grade 2 meningiomas – a retrospective feasibility study in a patient cohort with resected meningiomas in New Zealand
14.09.2023
12:45 – 12:51 4 Min. 2 Min.
ePoster Talk
PS2-NO-A41
Utility of DNA-methylation profiling and Integrated Molecular-Morphologic Meningioma classification as a prognostic biomarker in CNS WHO grade 2 meningiomas – a retrospective feasibility study in a patient cohort with resected meningiomas in New Zealand